Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab Long-term Extension Study in Multiple Myeloma
NCT05438043Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Jan 2029
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of daratumumab in multiple myeloma (MM) and smoldering multiple myeloma (SMM), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Serious Adverse Events, Number of Participants with AEs of Special Interest and 2 more. Started Dec 2022; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT05438043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438043.